Crinetics (CRNX) director sells 3,000 shares at $40 in planned trade
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share. The trade occurred on July 2, 2026 and was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, he directly holds 19,225 Crinetics shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 3,000 shares ($120,000)
Net Sell
1 txn
Insider
Vivaldi Coelho Rogerio
Role
null
Sold
3,000 shs ($120K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,000 | $40.00 | $120K |
Holdings After Transaction:
Common Stock — 19,225 shares (Direct, null)
Footnotes (1)
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.
Key Figures
Shares sold: 3,000 shares
Sale price: $40.00 per share
Shares held after sale: 19,225 shares
+1 more
4 metrics
Shares sold
3,000 shares
Open-market sale on July 2, 2026
Sale price
$40.00 per share
Price for Common Stock sold
Shares held after sale
19,225 shares
Director’s direct holdings following transaction
Net shares sold
3,000 shares
Net-sell direction per transaction summary
Key Terms
Rule 10b5-1 trading plan, open market transactions, Common Stock, Form 4
4 terms
Rule 10b5-1 trading plan regulatory
"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open market transactions financial
"The common stock was sold by the Reporting Person in open market transactions on the transaction date"
Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.
Common Stock financial
"The common stock was sold by the Reporting Person in open market transactions"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"The sale reported in this Form 4 was effected automatically"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Crinetics (CRNX) director Vivaldi Coelho Rogerio report?
Director Vivaldi Coelho Rogerio reported selling 3,000 shares of Crinetics Common Stock. The shares were sold in an open-market transaction at $40.00 per share, and the transaction was disclosed on a Form 4 insider filing.
Was the Crinetics (CRNX) insider sale made under a Rule 10b5-1 trading plan?
Yes, the sale was executed under a Rule 10b5-1 trading plan. The plan was adopted by the reporting person on December 11, 2025, and the transaction was carried out automatically pursuant to that pre-arranged plan.
What type of security did the Crinetics (CRNX) director sell in this Form 4?
The director sold shares of Crinetics Common Stock. The Form 4 specifies that 3,000 non-derivative Common Stock shares were sold in open-market transactions at a sale price of $40.00 per share.
Does the Crinetics (CRNX) Form 4 indicate an open-market sale or a private transaction?
The Form 4 describes the transaction as an open-market sale of Common Stock. Footnotes clarify that the common stock was sold by the reporting person in open market transactions at a sale price of $40.00 per share.